Literature DB >> 8536704

Crystal structure of the transthyretin--retinoic-acid complex.

G Zanotti1, M R D'Acunto, G Malpeli, C Folli, R Berni.   

Abstract

Retinoids are quite insoluble and chemically unstable compounds in the aqueous medium, such that natural retinoids need to be bound to specific retinoid-binding proteins to be protected, solubilized and transported in body fluids. All-trans retinoic acid exhibits a relatively high affinity for thyroxine-binding transthyretin in vitro and this protein is a good candidate for the transport of retinoic acid administered as pharmacological or antitumor agent. To define structural features essential for the recognition by transthyretin of a ligand which is structurally unrelated to thyroxine, we have cocrystallized human transthyretin with retinoic acid and determined its structure at 0.18-nm resolution. The retinoid fits into the two chemically identical thyroxine-binding sites, which are located in the central channel that runs through the tetrameric transthyretin. The cyclohexene ring of the bound retinoid is innermost, occupying the same position of the phenolic ring of the bound 3,3'-diiodo-L-thyronine, whereas the carboxylate group, like the same group of the thyroid hormone, participates in an ionic interaction with the Lys15 side chain at the entrance of the channel. Despite the fact that transthyretin was cocrystallized with all-trans-retinoic acid, the isoprene chain of the bound retinoid has been found in a non-extended conformation. This feature, that allows the carboxylate to orient in a manner suitable for ion-pair association with the Lys15 side chain, is attributable to the conversion of all-trans-retinoic acid into cis-isomers or folded conformers. It is concluded that the presence, in an essentially hydrophobic molecular core of the appropriate size, of a negatively charged group at the correct position is a crucial requirement for ligand-transthyretin recognition. Whereas the binding of the ligand has no remarkable consequences for the protein structure, all-trans-retinoic acid undergoes structural changes such as to interact favorably with residues present in the thyroxine-binding sites, resembling roughly the natural ligand.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8536704     DOI: 10.1111/j.1432-1033.1995.563_b.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  10 in total

1.  QM/MM refinement and analysis of protein bound retinoic acid.

Authors:  Xue Li; Zheng Fu; Kenneth M Merz
Journal:  J Comput Chem       Date:  2011-11-23       Impact factor: 3.376

Review 2.  Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses.

Authors:  Stephen Connelly; Sungwook Choi; Steven M Johnson; Jeffery W Kelly; Ian A Wilson
Journal:  Curr Opin Struct Biol       Date:  2010-02-03       Impact factor: 6.809

3.  Transthyretin proteoforms of intraocular origin in human subretinal fluid.

Authors:  Jianzhong Chen; Dongfeng Cao; Seth D Fortmann; Christine A Curcio; Richard M Feist; Jason N Crosson
Journal:  Exp Eye Res       Date:  2022-06-26       Impact factor: 3.770

4.  Three Newly Recognized Likely Pathogenic Gene Variants Associated with Hereditary Transthyretin Amyloidosis.

Authors:  Jignesh K Patel; Andrew M Rosen; Adam Chamberlin; Benjamin Feldmann; Christian Antolik; Heather Zimmermann; Tami Johnston; Arvind Narayana
Journal:  Neurol Ther       Date:  2022-08-06

5.  Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis.

Authors:  M R Almeida; A M Damas; M C Lans; A Brouwer; M J Saraiva
Journal:  Endocrine       Date:  1997-06       Impact factor: 3.633

6.  Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation.

Authors:  Ricardo Sant'Anna; Maria Rosário Almeida; Nathalia Varejāo; Pablo Gallego; Sebastian Esperante; Priscila Ferreira; Alda Pereira-Henriques; Fernando L Palhano; Mamede de Carvalho; Debora Foguel; David Reverter; Maria João Saraiva; Salvador Ventura
Journal:  Sci Rep       Date:  2017-03-24       Impact factor: 4.379

7.  Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis.

Authors:  Satheesh K Palaninathan; Nilofar N Mohamedmohaideen; Elisabetta Orlandini; Gabriella Ortore; Susanna Nencetti; Annalina Lapucci; Armando Rossello; Joel S Freundlich; James C Sacchettini
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

8.  Transthyretin Amyloid Fibril Disrupting Activities of Extracts and Fractions from Juglans mandshurica Maxim. var. cordiformis (Makino) Kitam.

Authors:  Niraj Chaudhary; Ryoko Sasaki; Tsuyoshi Shuto; Masato Watanabe; Teppei Kawahara; Mary Ann Suico; Takeshi Yokoyama; Mineyuki Mizuguchi; Hirofumi Kai; Hari Prasad Devkota
Journal:  Molecules       Date:  2019-01-30       Impact factor: 4.411

Review 9.  Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design.

Authors:  Lidia Ciccone; Nicoló Tonali; Susanna Nencetti; Elisabetta Orlandini
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 10.  Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine.

Authors:  Raquel Ferreira; Joseph Napoli; Tariq Enver; Liliana Bernardino; Lino Ferreira
Journal:  Nat Commun       Date:  2020-08-26       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.